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The Japanese ABO-Incompatible Transplantation Committee officially collected and analyzed data on
pediatric ABO-incompatible living-donor kidney transplantation in July 2012. The age of a child was defined
as ,16 years, and 89 children who had undergone ABO-incompatible living-donor kidney transplantation
from 1989 to 2011 were entered in a registry. These data were presented as the Japanese registry of pediatric
ABO-incompatible living-donor kidney transplantation at the regional meetings of the International
Pediatric Transplantation Association (IPTA) in Nagoya in September 2012 and in Sao Paulo in November
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ABO-incompatible (ABOi) living-donor kidney trans-
plantation (ABOiLDKTx) has been adopted for children
and adults. In the Japanese ABOiLDKTx registry, 89 of
2,218 recipients of ABOiLDKTx were children aged ,16
years. The donors were primarily parents (n = 86; 98%).
Overall graft survival rates in children (aged ,16 years)
and adults (aged $16 years) were, respectively, 94% and
93% at 1 year, 90% and 85% at 5 years, and 85% and 70%
at 10 years post-transplantation. Consequently, the graft
survival rate in children was significantly better than in
adults (p,0.05). Graft survival rates in children adminis-
tered cyclosporine (CsA; n = 41) or tacrolimus (FK; n = 48)
were 95% and 94%, respectively. No significant differ-
ence in patient or graft survival rates was observed
between children administered CsA and those adminis-
tered FK.
In addition,we retrospectively studied pediatric ABOiLDKTx
in the Department of Nephrology and Pediatric Nephrology,
Toho University Omori Medical Center, as a single-center
study. In total, 21 children (,20 years of age, as defined by
the North American Pediatric Renal Trials and Collaborative
Studies (NAPRTCS)) underwent ABOiLDKTx at the Toho
University Omori Medical Center. Graft and patient survival
rates were both 95% 10 years post-Tx. The administration of
rituximab (RIT) without splenectomy was effective for
desensitization pre-Tx to suppress anti-donor blood-group
antibody (ADBGAB) IgG. ABOiLDKTx should be considered
for children with end-stage renal failure.
The outcome of ABOiLDKTx was not expected to be
favorable .20 years ago because it was commonly believed
that hyperacute rejection could occur in any recipient with
a blood group incompatible with that of the donor.
However, the incidence of hyperacute rejection is incredibly
low (1), and this rejection never occurs if RIT, mycopheno-
late mofetil (MMF), a steroid, and a calcineurin inhibitor
(CNI) are used as desensitizing agents before transplanta-
tion. ABOiLDKTx is now very popular in Japan because
its outcomes have been demonstrated to be similar to
those of ABOcLDKTx (2,3). In addition, pediatric KTx has
been adopted for ABOiLDKTx. We collected and analyzed
data from all pediatric kidney transplant centers to generate
a registry of pediatric ABOiLDKTx under the Japanese
ABO-Incompatible Transplantation Committee. We also
studied pediatric ABOiLDKTx at the Toho University
Omori Medical Center as a single-center study. Children
with end-stage renal failure tend to become growth
retarded. In addition, peritoneal dialysis cannot be con-
tinued in children for an extended period. Therefore,
ABOiLDKTx should be considered earlier or preemptively
for children.
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& PATIENTS AND METHODS
Recipients and donors
In the Japanese registry, the recipient and donor ages at
the time of ABOiLDKTx were 11.1¡3.0 years and 41.4¡6.7
years, respectively. The recipients included 54 boys (61%)
and 35 girls (39%), and the donors included 27 males and 62
females. In total, 86 parents (98%) and three other relatives
acted as donors for the recipients. The control group
comprised 2,129 adult recipients of ABOiLDKTx who were
$16 years of age.
The recipient and donor ages at the time of ABOiLDKTx
in the Toho University single-center study were 13.2¡4.0
years and 42.5¡6.4 years, respectively. The recipients
included 10 boys (48%) and 11 girls (52%). In total, 21
(100%) parents acted as donors for the recipients.
ABO blood group-incompatible matches
In the Japanese registry of ABOiLDKTx, ABO blood
group-incompatible matches included 41 A to O, 16 B to O,
13 AB to A, 8 AB to B, 6 A to B, and 5 B to A. The ABO blood
group-incompatible matches in the Toho University single-
center study included 6 A to O, 5 B to O, 4 AB to A, 3 AB to
B, 2 A to B, and 1 B to A.
Immunosuppression
In the Japanese registry of ABOiLDKTx, immunosuppres-
sion in the induction period involved the use of RIT (n=17);
basiliximab (BXM; n=51); splenectomy (n=55); and azathio-
prine (AZ; n=38) or MMF (n=51) and CsA (n=48) or FK
(n=41). CsA was replaced with FK in 9 recipients during the
maintenance period. Immunosuppression in the induction
period in the Toho University single-center study involved the
use of RIT (n=7); BXM (n=12); splenectomy (n=14); and AZ
(n=8) or MMF (n=13) and CsA (n=11) or FK (n=10). CsA
was replaced with FK in 1 recipient after treatment for acute
rejection, and FK was replaced with CsA in 1 recipient who
developed post-transplant diabetes mellitus.
The 21 recipients at Toho University were divided into
two groups based on immunosuppression. Fourteen reci-
pients who were not administered RIT with splenectomy
were categorized into group I. Seven recipients who were
administered RIT without splenectomy were categorized
into group II.
Preconditioning
ADBGAB was removed by double-filtration plasmapher-
esis and plasma exchange using AB blood-group plasma.
The ADBGAB titer was adjusted to #32 times before
ABOiLDKTx. AZ or MMF and steroid were administ-
ered for desensitization beginning 10–30 days before
ABOiLDKTx. RIT (100 mg) was administered 1–2 times 1
day and/or 14 days before ABOiLDKTx.
Post-transplant conditioning
Plasmapheresis, plasma exchange, and intravenous immu-
noglobulin (IVIG) administration were not performed post-
transplantation.
Anti-donor blood-group antibody
ADBGAB titers were measured before and after trans-
plantation. Maximum ADBGAB values before and after
ABOiLDKTx were compared between groups I and II.
Statistics
Patient and graft survival rates were calculated by the
Kaplan-Meier method. A p-value ,0.05 was considered
significant.
& RESULTS
Pediatric ABOiLDKTx registry under the
ABO-Incompatible Transplantation Committee
a) Number of pediatric ABOiLDKTx cases in Japan
A total of 2,218 ABOiLDKTx procedures were conducted
in Japan from 1989–2011. The number of ABOiLDKTx cases
has increased annually, and 280 ABOiLDKTx procedures
were performed in 2011. Among the 2,218 recipients of
ABOiLDKTx, 89 children aged ,16 years had undergone
ABOiLDKTx (Figure 1). Therefore, the rate of pediatric
Figure 1 - Annual Number of ABO-Incompatible Kidney Transplantations in Japan.
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ABOiLDKTx was only 4%, and 0–7 children underwent
ABOiLDKTx every year in Japan (Figure 1).
b) Patient and graft survival rates
Overall patient and graft survival rates in the 89 pediatric
cases of ABOiLDKTx (aged ,16 years) were, respectively,
99% and 94% at 1 year, 99% and 93% at 3 years, 97% and
90% at 5 years, 97% and 80% at 10 years, and 81% and 68%
at 20 years post-transplantation (Figure 2). In contrast, graft
survival rates in 2,129 adult cases of ABOiLDKTx ($16
years) were 93% at 1 year, 89% at 3 years, 85% at 5 years,
70% at 10 years, and 50% at 20 years post-transplantation.
Graft survival rates were significantly better in the pediatric
cases of ABOiLDKTx than in the adult cases of ABOiLDKTx
(p,0.05; Figure 3).
Graft survival rates in pediatric recipients of ABOiLDKTx
who received CsA (n = 39) or FK (n = 50) were, respectively,
95% and 94% at 1 year, 95% and 91% at 3 years, 92% and
88% at 5 years, 88% and 81% at 10 years, and 68% and 81%
at 20 years post-transplantation. No significant difference
in graft survival rates was observed between pediatric
recipients of ABOiLDKTx who were administered CsA and
those who received FK.
Graft survival rates in pediatric recipients of ABOiLDKTx
administered RIT without splenectomy (n= 17) and those
not administered RIT with splenectomy (n = 18) were 93%
and 100% at 1 and 3 years post-transplantation, respectively.
Toho University single-center study
a) Acute rejection
Acute rejection developed in 8 of 21 recipients. Borderline
rejection, grade 1a rejection, and grade 1b rejection, based
on the Banff classification, were diagnosed in 3, 4, and 1
recipients, respectively. Eight recipients were administered
250–500 mg steroid pulse therapy. Deoxyspergualin and
muromonab-CD3 were administered for steroid-resistant
rejection in 3 and 1 recipients, respectively.
Acute rejection occurred in 7 of 14 recipients who were
not administered RIT. In contrast, only 1 of 7 recipients
(14%) who was administered RIT developed acute grade 1a
rejection. No patient who was administered RIT developed
steroid-resistant rejection that was not treated with deox-
yspergualin and muromonab-CD3.
b) Infection
Eight recipients developed a cytomegalovirus (CMV)
infection diagnosed by antigenemia. Five of 8 recipients
had symptoms of CMV infection, such as fever, including
one with CMV pneumonitis. Eight recipients were adminis-
tered ganciclovir. One recipient had herpes zoster in the
right foot and was administered acyclovir. Hemorrhagic
cystitis due to adenovirus occurred in one recipient and was
cured by MMF withdrawal. Two recipients had wound
infections, and one developed a pelvic abscess. The bacterial
infections in these two recipients were treated by drainage
of pus and antibiotic therapy.
c) Other complications
Lymphocele, ureteral stenosis, and B cell lymphoma
occurred in one recipient each.
d) Patient and graft survival rates (Figure 4)
One recipient died of obstructive cardiomyopathy with a
functioning graft 6 months post-Tx. The remaining 20
recipients survived for a minimum of 13 months to a
maximum of 20 years post-Tx. The patient survival rate was
95% at 10 years post-Tx. Two recipients lost graft function
and were reintroduced to hemodialysis 13 years or 10 years
and 10 months post-Tx, respectively. Patient and graft
survival rates were 95% at 1–10 years post-Tx. One of the
Figure 2 - Overall Patient and Graft Survival Rates (Age ,16 years).
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two recipients who lost graft function had donor-specific
HLA antibodies, and a biopsy demonstrated chronic anti-
body-mediated rejection. Another recipient developed
chronic allograft nephropathy without donor-specific HLA
antibodies.
e) Sequential change in ADBGAB IgG titers
The maximum ADBGAB IgG titers before ABOiLDKTx
were 75.9¡138.9 and 57.4¡85.2 in groups I and II,
respectively (p= 0.38; Figure 5A). The ADBGAB IgG titers
in all 21 recipients immediately before ABOiLDKTx were
equal to or less than 32 times in terms of preconditioning.
The maximum ADBGAB IgG titers after ABOiLDKTx were
44.0¡31.5 and 7.7¡7.2 in groups I and II, respectively
(p= 0.005; Figure 5B). The maximum ADBGAB IgG titers
post-transplantation were significantly higher than the
maximum IgG titers pre-transplantation in 12 of 14
recipients. However, no recipients belonged to group II.
& DISCUSSION
ABOiLDKTx has been performed in Japan since 1989. The
number of ABOiLDKTx cases has increased annually since
2001, and 280 ABOiLDKTx procedures were performed in
2011. ABOiLDKTx was introduced in Japan because of an
extreme shortage of deceased donors and an unexpectedly
low incidence of hyperacute rejection (3). In addition,
patient and graft survival from ABOiLDKTx have been
similar to survival from ABOc since 2001 (2,3). This result
may have been caused by the administration of RIT and
MMF as desensitizing agents pre-Tx at most kidney
transplant centers in Japan since 2000 (4).
ABOiLDKTx has also been performed in children with
end-stage renal failure since 1989. In fact, 2 children
underwent ABOiLDKTx in 1989 (Figure 1). Overall, the
graft survival rate in pediatric ABOiLDKTx was better
than in adult ABOiLDKTx. More than 90% of the donors in
pediatric ABOiLDKTx were parents. The donor age in
pediatric ABOiLDKTx was younger than in adult
ABOiLDKTx. It is well known that graft survival in KTx
depends on donor age. A younger donor provides longer
graft survival. No difference in graft survival rates was
observed between pediatric ABOiLDKTx recipients admi-
nistered CsA and those administered FK. FK tended to be
used for immunologically high-risk patients, such as HLA-
sensitized recipients. However, the immunological risk
in ABOiLDKTx recipients could be lower than in HLA-
sensitized recipients. Antibody-mediated rejection is avoid-
foed because antibody production is directly suppressed by
RIT and MMF and is also indirectly suppressed by CNI.
According to the NAPRTCS 2010 Annual Transplant Report
(5), the graft survival rates in pediatric LDKTx recipients
aged ,20 years are 95.5% at 1 year, 91.3% at 3 years, 85.7%
at 5 years, and 80.5% at 7 years post-Tx. In the Japanese
ABOiLDKTx registry, graft survival rates in children aged
,16 years were 94% at 1 year, 93% at 3 year, and 90% at 5
Figure 3 - Graft Survival of ABOi Compared between Pediatric and Adult Recipients.
Figure 4 - Patient and Graft Survival from Pediatric ABOi at Toho
University.
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years post-Tx. Although the definition of the age of a child is
different between the NAPRTCS (age ,20 years) and the
Japanese registry of pediatric ABOiLDKTx (age ,16 years),
graft survival rates were not different. However, the
definition of the age of a child at Toho University was the
same as that provided by the NAPRTCS. The graft survival
rate in pediatric ABOiLDKTx at Toho University was better
than that reported by theNAPRTCS. However, the number of
ABOiLDKTx procedures at Toho University was small, and
most of the NAPRTCS data included pediatric ABOcLDKTx.
The incidences of acute rejection and antibody-mediated
rejection in a Japanese study comparing pediatric ABOc and
ABOiLDKTx were significantly higher in ABOiLDKTx than
in ABOc. However, no difference in patient and graft survival
rates was observed between the groups (97%, 92%, 88%, and
86%, respectively, at 10 years post-transplantation).
It appeared that there was a lower incidence of antibody-
mediated rejection in pediatric recipients of ABOiLDKTx
who were administered RIT without splenectomy, and no
patient developed steroid-resistant antibody-mediated rejec-
tion at Toho University. The graft survival rate in recipients
administered RIT without splenectomy was not different
from that in recipients not administered RIT with splenect-
omy in the Japanese registry of pediatric ABOiLDKTx.
Recipients who were administered RIT without splenectomy
at Toho University tended to have a lower incidence of
acute rejection, although the difference was not significant. In
addition, the recipients who were administered RIT without
splenectomy showed lower ADBGAB IgG titers post-Tx than
those not administered RIT with splenectomy. ABOiLDKTx
recipients not administered RIT with splenectomy tended to
have increased ADBGAB titers that were greater than the
maximum pre-Tx titer within 10 days (6). RIT appeared to be
a stronger suppressor of antibody production than splenect-
omy was. Splenectomy is not necessary to avoid hyperacute
rejection and antibody-mediated rejection in patients under-
going pediatric ABOiLDKTx if RIT is administered as a
desensitizing agent pre-transplantation (7). A splenectomy
should be avoided in children to prevent pneumococcal
infection and other complications, although our 14 pediatric
recipients who underwent splenectomy at Toho University
had no serious complications.
The incidence of acute rejection in pediatric recipients
administered RIT without splenectomy tended to be lower
than in those not administered RIT with splenectomy in the
Toho University single-center study. In particular, steroid-
resistant rejection did not occur in any pediatric recipients
administered RIT without splenectomy.
The maximum ADBGAB IgG titers post-transplantation in
group II (pediatric recipients of ABOiLDKTx who were
administered RIT without splenectomy) were significantly
lower than those in group I (who were not administered RIT
without splenectomy). The ADBGAB IgG titers increased in
12 of 14 recipients in group I post-Tx; however, the titers in
group II did not increase. Post-transplant plasmapheresis
or adsorption is routinely performed in European and US
reports (7,8). Therefore, these reports cannot show the natural
course of the ADBGAB titers post-Tx. In contrast, we did not
perform post-transplant plasmapheresis or exchange at Toho
University. Therefore, we were able to analyze the sequential
changes in ADBGAB titers during immunosuppression.
Takahashi reported that antibody-mediated rejection related
to ABO blood-group incompatibility does not occur due to
natural ADBGAB, but rather to de novo ADBGAB (9).
Desensitization with RIT, MMF, and CNI pre-Tx and
immunosuppression of B cells post-Tx in ABOiLDKTx
recipients are more important than plasmapheresis pre- and
post-Tx. The Japanese ABO-Incompatible Transplantation
Committee recently recommended that plasmapheresis or
exchange should not be performed as preconditioning if the
ADBGAB IgG titer is #64 times higher in recipients and
stated that routine plasmapheresis is not necessary post-Tx.
These recommendations are beneficial for small childrenwith
peritoneal dialysis because they do not require blood access
and a catheter for plasmapheresis or exchange.
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